What is the PBPKPlus™ Module?
Ranked as the #1 PBPK software in In Vitro-In Vivo Extrapolation (IVIVE) & PBPK modeling by Pfizer!
(Cole et al., 2nd Asian Pacific Regional ISSX Meeting, May 2008, Shanghai, China)
NEW! Chinese and hepatic impairment populations groups.
Upgraded! Infant PBPK models – easily perform pediatric PBPK modeling to capture the pharmacokinetics and pharmacodynamics in infants as young as 16 weeks premature, with automatic scaling of physiological parameters (e.g., hematocrit, plasma protein levels) with age!
Want to see the PBPKPlus Module in action? Take a look at some recent posters focused on pediatric PBPK simulations. More applications can be seen while visiting the DDI Module page or our Resource Center.
Prediction of Acyclovir Pharmacokinetics in Pediatric Populations using a Physiologically Based Pharmocokinetic (PBPK) ModelLearn More
Lukacova, V., M.B. Bolger, W.S. Woltosz
Prediction of Valsartan Pharmacokinetics in Pediatric Population using Physiologically Based Pharmacokinetic (PBPK) ModelLearn More
Lukacova, V., M.B. Bolger, W.5. Woltosz
Physiologically based pharmacokinetic (PBPK) model for prediction of vancomycin pharmacokinetics in childrenLearn More
Lukacova, V. , W.S. Woltosz,
Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK modelLearn More
Gao ZW, Zhu YT, Yu MM, Zan B, Liu J, Zhang YF, Chen XY, Li XN, Zhong DF